专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2021204714A1 CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES 审中-公开
公开(公告)号：WO2021204714A1
公开(公告)日：2021-10-14
申请号：PCT/EP2021/058775
申请日：2021-04-01
申请人： ARES TRADING S.A.
发明人： VASSALLO, Oscar
IPC分类号： G01N27/447 , C07K16/06
摘要： The invention described herein relates to an improved method for analytical capillary gel electrophoresis (CGE) for complex biologic molecules. The methods for the improved CGE include steps for the partial reduction of the biologic analyte molecule for use as calibration standard and use such partially reduced calibration sample to obtain an improved calibration curve for CGE to be used with biologic analyte molecules.

2. 发明申请

WO2019121961A2 METHODS FOR MODULATING PROTEIN MANNOSYLATION PROFILES USING A POLYETHER IONOPHORE 审中-公开
公开(公告)号：WO2019121961A2
公开(公告)日：2019-06-27
申请号：PCT/EP2018/085909
申请日：2018-12-19
申请人： ARES TRADING S.A.
发明人： BRUHLMANN, David , VUILLEMIN, Thomas , JORDAN, Martin , BROLY, Hervé
IPC分类号： C12P21/00 , C12N5/16 , C07K16/00 , A61K39/395
CPC分类号： C12P21/005 , C07K16/00 , C07K2317/41
摘要： The present invention relates to methods and compositions for modulating mannosylation profile of recombinant proteins expressed by mammalian host cells during the cell culture process, using a polyether ionophore.

3. 发明申请

WO2018184692A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
公开(公告)号：WO2018184692A1
公开(公告)日：2018-10-11
申请号：PCT/EP2017/058394
申请日：2017-04-07
申请人： ARES TRADING S.A.
发明人： BADIALI, Luca , GERRING, David , JEZEK, Jan
IPC分类号： A61K9/00 , A61K39/395 , A61K47/10 , A61K47/18 , A61K47/26
CPC分类号： A61K9/0019 , A61K39/39591 , A61K47/10 , A61K47/183 , A61K47/26 , C07K16/241
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, arginine and/or methionine, and a small polyol stabiliser such as glycerol. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.

4. 发明申请

WO2018078162A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药物组合物
公开(公告)号：WO2018078162A1
公开(公告)日：2018-05-03
申请号：PCT/EP2017/077793
申请日：2017-10-30
申请人： ARES TRADING S.A.
发明人： JEZEK, Jan , BADIALI, Luca , GERRING, David
IPC分类号： A61K9/00 , A61K47/18 , A61K9/08 , A61K38/16
摘要： The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of tocilizumab, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
摘要翻译：本发明涉及一种新型蛋白质制剂。具体而言，本发明涉及托西珠单抗的液体药物组合物，制备该组合物的方法，包含该组合物的试剂盒，包含该组合物的包装以及使用该组合物和/或包装的治疗方法。

5. 发明申请

WO2018060210A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药物组合物
公开(公告)号：WO2018060210A1
公开(公告)日：2018-04-05
申请号：PCT/EP2017/074413
申请日：2017-09-26
申请人： ARES TRADING S.A.
发明人： DEL RIO, Alessandra , SABINA, Carmela
IPC分类号： A61K9/00 , A61K38/00 , A61K9/08 , A61P19/02 , A61K47/18 , A61K47/26
摘要： The present invention relates to a novel protein formulation. In particular, the invention relates to a liquid pharmaceutical composition of an antibody directed to Interleukin-6 receptor, a method of manufacturing the composition, a kit including the composition, a package including the composition and to methods of treatment using the composition and/or package.
摘要翻译：本发明涉及一种新型蛋白质制剂。具体而言，本发明涉及针对白细胞介素-6受体的抗体的液体药物组合物，制备该组合物的方法，包含该组合物的试剂盒，包含该组合物的包装和使用该组合物的治疗方法和/或封装

6. 发明申请

WO2018046769A1 METHODS FOR MODULATING PRODUCTION PROFILES OF RECOMBINANT PROTEINS 审中-公开
标题翻译：调节重组蛋白质生产特征的方法
公开(公告)号：WO2018046769A1
公开(公告)日：2018-03-15
申请号：PCT/EP2017/072936
申请日：2017-09-12
申请人： ARES TRADING S.A.
发明人： BIELSER, Jean-Marc , DESMURGET, Caroline
IPC分类号： C12N5/00 , C12P1/00 , C07K16/18
摘要： The present invention relates to methods and compositions for culturing a host cell expressing a recombinant protein in a cell culture medium supplemented with feeds comprising effective amounts of valeric acid, whereby viability of the cells and production of said protein are increased relative to cells grown with feeds comprising no valeric acid.
摘要翻译：本发明涉及用于在补充有包含有效量的戊酸的饲料的细胞培养基中培养表达重组蛋白的宿主细胞的方法和组合物，由此细胞的生存力和所述蛋白的产生相对于用不含戊酸的饲料生长的细胞增加。

7. 发明申请

WO2016120387A1 IMMUNOASSAYS FOR HIGH POSITIVELY CHARGED PROTEINS 审中-公开
标题翻译：免疫功能高度积极的蛋白质
公开(公告)号：WO2016120387A1
公开(公告)日：2016-08-04
申请号：PCT/EP2016/051808
申请日：2016-01-28
申请人： ARES TRADING S.A.
发明人： BERTOTTI, Elisa , CASTAGNA, Valeria
IPC分类号： G01N33/53 , G01N33/68
CPC分类号： G01N33/6887 , C12Q1/40 , G01N33/5306 , G01N33/54306 , G01N35/0099 , G01N35/10 , G01N35/1095 , G01N2035/00495 , G01N2333/50 , G01N2800/102
摘要： The present invention relates to immunoassays for quantification of a high positively charged protein, such as a FGF-18 protein, in human synovial fluid sample.
摘要翻译：本发明涉及用于在人滑膜样品中定量高带正电荷的蛋白质，例如FGF-18蛋白质的免疫测定。

8. 发明申请

WO2015177058A1 LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：液体药用组合物
公开(公告)号：WO2015177058A1
公开(公告)日：2015-11-26
申请号：PCT/EP2015/060817
申请日：2015-05-15
申请人： ARES TRADING S.A.
发明人： RINALDI, Gianluca , FRATARCANGELI, Silvia , DEL RIO, Alessandra
IPC分类号： A61K9/00 , A61K38/00 , A61K47/18 , A61K47/26
CPC分类号： A61K39/39591 , A61K9/0019 , A61K47/183 , A61K47/26 , C07K16/241 , C07K2317/21 , C07K2317/76
摘要： The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an histidine buffering agent such as histidine (or histidine buffer system such as histidine/imidiazolium-histidine), and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
摘要翻译：本发明涉及阿达木单抗的新型液体药物组合物，其包括阿达木单抗或其生物相似物，组氨酸缓冲剂如组氨酸（或组氨酸缓冲体系如组氨酸/亚氨基唑 - 组氨酸）和糖稳定剂如海藻糖。这种组合组合物提供了具有稳定性（例如在储存和暴露于应力时）的制剂，其与本领域已知的那些相当或改善，并且具有较少的成分。这些进展将有助于阿达木单抗治疗以更低的成本变得更广泛地使用，并且延长预加载递送装置（例如预装注射器）的生存能力，以减少不必要的药物浪费。

9. 发明申请

WO2015082578A1 MEDICAL DEVICE CONNECTION STATION 审中-公开
标题翻译：医疗设备连接站
公开(公告)号：WO2015082578A1
公开(公告)日：2015-06-11
申请号：PCT/EP2014/076482
申请日：2014-12-04
申请人： ARES TRADING S.A.
发明人： LAUCHARD, Gerhard , WALDER, Gerhard , LEGNER, Alexander , CHANIE, Eric , KOUVAS, Georgios
IPC分类号： G06F19/00 , G06F1/16
CPC分类号： G06F19/3418 , A61M5/31 , A61M15/009 , A61M2205/3553 , A61M2205/3569 , A61M2205/3584 , A61M2205/502 , A61M2205/52 , A61M2230/005 , G06F1/1632 , G06F19/00 , G06F19/3456 , G06F19/3462 , G06F19/3468 , G16H40/63 , H04L67/12 , H04L67/141 , H04L67/42
摘要： A medical device connection station comprising a body having a first portion of a docking interface to dock with a corresponding second portion of a docking interface of a medical device, a control unit controlling a medical device communication interface for communication with a docked medical device and controlling a server communication interface. The control unit is configured acquire medical data from a docked medical device via the medical device communication interface and is further configured to connect with and obtain a data session with the server system via the server communication interface, and to thereby transfer the medical data to the server system. The medical device connection station further comprises a lid connected to the body and movable between a first and second position, wherein in the first position the lid prevents first portion of the docking interface from docking with the second portion of the docking interface of the medical device, and wherein in the second position the first portion of the docking interface is operable to dock with the second portion of the docking interface. The medical device connection station comprises a lid movement sensing unit which is configured to sense movement of the lid between the first position and the second position and to thereby provide a signal to the control unit, the control unit configured to receive the signal to initiate the connection to the server system.
摘要翻译：一种医疗设备连接站，包括具有对接接口的第一部分的主体，该第一部分与医疗设备的对接界面的相应的第二部分对接;控制单元，其控制医疗设备通信接口以与对接的医疗设备进行通信并控制一个服务器通信接口。控制单元经由医疗设备通信接口从对接的医疗设备获取医疗数据，并且还被配置为经由服务器通信接口与服务器系统连接并获得数据会话，从而将医疗数据传送到服务器系统。医疗设备连接站还包括连接到主体并可在第一和第二位置之间移动的盖子，其中在第一位置，盖子防止对接接口的第一部分与医疗设备的对接接口的第二部分对接，并且其中在所述第二位置中，所述对接接口的所述第一部分可操作以与所述对接接口的所述第二部分对接。医疗装置连接站包括盖运动检测单元，其被配置为感测盖在第一位置和第二位置之间的移动，从而向控制单元提供信号，该控制单元被配置为接收信号以启动连接到服务器系统。

10. 发明申请

WO2014012614A1 FUSED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS 审中-公开
标题翻译：作为GAMMA秘密调节剂的熔融三唑衍生物
公开(公告)号：WO2014012614A1
公开(公告)日：2014-01-23
申请号：PCT/EP2013/001774
申请日：2013-06-14
申请人： ARES TRADING S.A.
发明人： WHITTAKER, Ben , STEELE, Chris , HARDICK, David , MITCHELL, Dale , POMEL, Vincent , QUATTROPANI, Anna , BEHER, Dirk
IPC分类号： C07D471/04 , C07D487/04 , C07D498/04 , A61K31/4192
CPC分类号： C07D487/04 , A61K31/4192 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/5383 , A61K45/06 , C07D471/04 , C07D498/04
摘要： The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.
摘要翻译：本发明提供用作γ-分泌酶调节剂（GSM）的用于治疗阿尔茨海默病和相关疾病的式（I）的稠合双环三唑衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式